Last Update 04 Aug 26
Fair value Increased 3.04%AGS: Execution Phase And Maybank Exit Will Shape Balanced Outlook
Analysts have increased their fair value estimate for Ageas from about €68 to about €70, reflecting updated assumptions on the discount rate, growth, profitability and P/E multiples, alongside recent Street price targets ranging from €70 to €86.30.
Analyst Commentary
Recent research on Ageas points to a split view on the stock, with some bullish analysts lifting price targets toward the upper end of the current range and others taking a more measured stance around €70.
These views cluster around two main themes, which are helpful for investors who are trying to judge whether the current valuation reflects execution risk and growth potential.
Bullish Takeaways
- Bullish analysts see the raised fair value and the higher Street target of €86.30 as support for upside potential relative to the current internal estimate of about €70 per share.
- The higher target close to €86 is described as an expression of confidence that Ageas can deliver on the growth and profitability assumptions that underpin richer P/E multiples.
- Supportive research highlights what is described as an improving execution phase after prior acquisitions, which some investors may interpret as a path to more consistent earnings and capital returns.
- The clustering of targets from €70 to €86.30 is viewed by bullish analysts as evidence that the stock is still not priced for more optimistic growth and margin scenarios.
Bearish Takeaways
- More cautious analysts, including those at Goldman Sachs, anchor their view closer to €70, which sits very near the updated fair value estimate and implies limited upside from current assumptions.
- The shift from an acquisition phase to an execution phase is seen as a risk for Ageas if integration or delivery on planned improvements takes longer or costs more than expected.
- Bearish analysts question whether the higher P/E multiples embedded in the top end of the target range can be justified without clearer evidence on sustainable profitability.
- The spread between the €70 and €86.30 price targets is presented as a sign of uncertainty around how much growth Ageas can achieve from its current business mix, which may keep some investors cautious.
What’s in the News for Ageas
- Ageas agreed to sell its 30.95% stake in Maybank Ageas Holdings Berhad to joint venture partner Maybank for a total cash consideration equivalent to €1.1b, capturing value from a 25 year partnership in the Malaysian and Singaporean insurance markets. Source: company announcement on the Maybank Ageas Holdings Berhad transaction.
- The Maybank Ageas Holdings Berhad sale is expected to be completed in 2026, subject to regulatory approvals, and is described as solvency accretive for Ageas. Source: company announcement on the Maybank Ageas Holdings Berhad transaction.
- Ageas SA/NV approved a gross cash dividend of €3.75 per share for the financial year 2025, with an interim dividend of €1.50 per share already paid in December 2025 and a final dividend of €2.25 per share scheduled with an ex dividend date of 3 June 2026 and payment date of 5 June 2026. Source: company key developments disclosure.
Valuation Changes for Ageas
- Fair value has moved from about €68.00 to about €70.06 per share, which is a small upward adjustment.
- The discount rate has fallen slightly from 6.58% to about 6.49%.
- The euro revenue growth assumption has edged down from about 11.13% to about 11.06%.
- The euro profit margin assumption has been trimmed from about 14.38% to about 13.51%.
- The future P/E has risen from about 8.36x to about 9.16x, which indicates a modestly higher valuation multiple for Ageas in the updated model.
Catalysts
About ageas
Ageas is an international insurance group providing life, non life and reinsurance solutions across Europe and Asia.
What are the underlying business or industry changes driving this perspective?
- Shift toward participating life products in China and other Asian markets is improving capital efficiency and reducing interest rate sensitivity, supporting more resilient earnings growth and potentially higher, more stable net margins over time.
- Consistently strong underwriting discipline in Non Life, reflected in a combined ratio of 92.1% and ongoing portfolio pruning in weaker segments, positions Ageas to sustain attractive technical profitability and expand operating margins through the cycle.
- Growing contribution from Asia and Europe, with higher volumes in short term life and improved new business margins, should translate into structurally higher life inflows and CSM growth, underpinning future revenue and earnings expansion.
- Robust balance sheet with a pro forma Solvency II ratio around 205% and strong operational capital generation enables continued dividend growth and disciplined M&A, which can enhance earnings per share and support total shareholder returns.
- Integration of esure and Saga, alongside ongoing pricing discipline in the U.K. motor and household markets, is expected to unlock meaningful cost and revenue synergies from 2028, driving incremental Non Life revenues and improving group net margins.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming ageas's revenue will grow by 11.1% annually over the next 3 years.
- Analysts assume that profit margins will shrink from 18.2% today to 13.5% in 3 years time.
- Analysts expect earnings to remain at the same level they are now, that being €1.7 billion (with an earnings per share of €8.7). However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €1.9 billion in earnings, and the most bearish expecting €1.2 billion.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 9.2x on those 2029 earnings, up from 8.2x today. This future PE is greater than the current PE for the GB Insurance industry at 8.2x.
- Analysts expect the number of shares outstanding to decline by 0.18% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.49%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- A prolonged low or further declining interest rate environment in key Asian markets, especially China and Thailand, could pressure the returns on long duration guarantees and slow the pace at which valuation interest rate effects normalise. This would weigh on long term earnings growth and net margins in Life.
- The strategic shift in China from higher margin nonparticipating products to lower margin but more capital efficient participating products may not be fully offset by volume growth. This could lead to structurally lower profitability and constrain future revenue growth and earnings expansion from the region.
- Execution and integration risks around the esure and Saga acquisitions, including higher than expected integration costs, delays in achieving synergies or more persistent U.K. claims inflation, could erode the currently strong combined ratio and reduce group level operating margins and earnings from 2026 onward.
- Adverse developments in China tax rules, FX movements or regulatory metrics such as the illiquidity spread and valuation interest rate could reverse the current low tax benefit and strong capital generation. This could result in higher effective tax rates, more volatile earnings and reduced free cash flow available for shareholder returns.
- A normalisation or increase in natural catastrophe losses from the currently benign weather experience assumed in guidance, combined with persistent inflation in repair and claims costs, could drive the Non Life combined ratio closer to or above budgeted levels over the cycle. This would compress underwriting profitability and group net margins.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of €70.06 for ageas based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €86.3, and the most bearish reporting a price target of just €60.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €12.9 billion, earnings will come to €1.7 billion, and it would be trading on a PE ratio of 9.2x, assuming you use a discount rate of 6.5%.
- Given the current share price of €74.05, the analyst price target of €70.06 is 5.7% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on ageas?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.